Industry
Biotechnology
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Loading...
Open
27.30
Mkt cap
4.3B
Volume
2.8M
High
28.41
P/E Ratio
-253.64
52-wk high
28.41
Low
27.05
Div yield
N/A
52-wk low
9.81
Portfolio Pulse from
November 05, 2024 | 12:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 1:48 pm
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 1:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 9:53 am
Portfolio Pulse from Benzinga Insights
September 23, 2024 | 5:35 pm
Portfolio Pulse from Benzinga Insights
September 18, 2024 | 9:01 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 5:02 pm
Portfolio Pulse from Dylan Berman
September 18, 2024 | 2:40 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 1:13 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 11:21 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.